de Vries, C R
Kaufman, H L
Lattime, E C
Article History
First Online: 27 February 2015
Competing interests
: Dr Lattime is an inventor of the patented recombinant Vaccinia-GMCSF which has been licensed to Sillajen and is being studied as Pexa-Vec (JX-594). As such, he derives royalties and licensing fees from Thomas Jefferson University where the patent is held. Dr Howard Kaufman has a consulting/advisory role to Alkermes, Amgen, Merck, Merck Serono, Promethus, and currently has funding from Bristol-Meyers Squibb/Medarex. Dr de Vries has no conflict of interest.
Free to read: This content has been made available to all.